NCT00694980View on ClinicalTrials.gov

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2012

Conditions

Ulcerative Colitis

Interventions

DRUG

placebo

Intravenous and subcutaneous escalating doses

DRUG

rhuMAb Beta7

Intravenous and subcutaneous escalating doses

Trial Locations (30)

3000

Leuven

11021

Great Neck

13353

Berlin

24105

Kiel

27599

Chapel Hill

30308

Atlanta

32610

Gainesville

36207

Anniston

40536

Lexington

55905

Rochester

60431

Frankfurt

89081

Ulm

93053

Regensburg

94115

San Francisco

T2N 2T9

Calgary

T6G 2X8

Edmonton

V6Z 2K5

Vancouver

V8V 3P9

Victoria

N6A 4L6

London

H1T 2M4

Montreal

2333 ZA

Leiden

6229 HX

Maastricht

6525 GA

Nijmegen

3584 CX

Utrecht

BS2 8HW

Bristol

SE1 7EH

London

SW10 9NH

London

W12 0HS

London

NE1 4LP

Newcastle upon Tyne

NG7 2UH

Nottingham

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY